United States v. Brandyn Blatchford , 488 F. App'x 236 ( 2012 )


Menu:
  •                                                                              FILED
    NOT FOR PUBLICATION                               OCT 23 2012
    MOLLY C. DWYER, CLERK
    UNITED STATES COURT OF APPEALS                         U .S. C O U R T OF APPE ALS
    FOR THE NINTH CIRCUIT
    UNITED STATES OF AMERICA,                        No. 11-10431
    Plaintiff - Appellee,              D.C. No. CR-04-562-PCT-DGC
    v.
    MEMORANDUM *
    BRANDYN BLATCHFORD,
    Defendant - Appellant.
    Appeal from the United States District Court
    for the District of Arizona
    David G. Campbell, District Judge, Presiding
    Argued and Submitted October 17, 2012
    San Francisco, California
    Before: FISHER, TALLMAN, and CALLAHAN, Circuit Judges.
    Defendant-Appellant Brandyn Blatchford (“Blatchford”) appeals the district
    court’s imposition of a special condition of supervised release that he “shall
    participate in a mental health program as directed by the probation officer which
    *
    This disposition is not appropriate for publication and is not precedent
    except as provided by 9th Cir. R. 36-3.
    may include taking prescribed medication.” We have jurisdiction under 
    18 U.S.C. § 3742
     and 
    28 U.S.C. § 1291
    , and we affirm.
    The district court’s imposition of the disputed special condition was not an
    abuse of discretion.1 First, because the court did not make “‘on-the-record,
    medically-grounded findings that court-ordered medication [was] necessary to
    accomplish one or more of the factors listed in [18 U.S.C.] § 3583(d)(1),’” this
    condition “must ‘be understood as limited to those medications that do not
    implicate a particularly significant liberty interest of the defendant.’” United States
    v. Daniels, 
    541 F.3d 915
    , 926 (9th Cir. 2008) (some internal quotation marks and
    citations omitted) (quoting United States v. Cope, 
    527 F.3d 944
    , 954–55 (9th Cir.
    2008)). There is no reason to remand for clarification by the district court, which
    we assume was aware of this rule of interpretation when it imposed the special
    condition. See Fenner v. United States Parole Comm’n, 
    251 F.3d 782
    , 786 (9th
    1
    The government contends that we should review the district court’s
    imposition of the special condition for plain error rather than abuse of discretion.
    However, we need not determine whether this more deferential standard of review
    applies because Blatchford’s claims fail on abuse of discretion review.
    2
    Cir. 2001) (“[W]e assume that the district court knows and applies the law
    correctly.” (internal quotation marks and citation omitted)).2
    Second, the district court did not improperly delegate judicial authority to
    the probation officer. See United States v. Esparza, 
    552 F.3d 1088
    , 1091 (9th Cir.
    2009). Both at the revocation hearing and in the order revoking supervised release,
    the court ordered that Blatchford “shall participate in a mental health program,”
    which “may include taking prescribed medication,”3 and then properly delegated to
    the probation officer administrative details, such as where and when the treatment
    would take place. See United States v. Stephens, 
    424 F.3d 876
    , 880 (9th Cir.
    2005); see also United States v. Rearden, 
    349 F.3d 608
    , 619 (9th Cir. 2003) (giving
    the probation officer authority to select “the type and extent” of psychological or
    psychiatric counseling and/or a sex offender treatment program was not plainly
    erroneous).
    Finally, the special condition is, by its plain language, limited to medications
    prescribed by a medical professional in connection with the mental health program
    2
    Our decision does not prejudice Blatchford’s ability to challenge any
    specific medications prescribed during his period of supervised release that may
    implicate significant liberty interests. See United States v. Mullen, No. 07-50572,
    329 Fed. App’x 61, 65 (9th Cir. May 7, 2009) (mem.).
    3
    We understand the court’s use of the term “may” in this context to
    reflect the fact that medical professionals—not courts—prescribe medication.
    3
    ordered by the court. See Cope, 
    527 F.3d at 956
     (“[T]he requirement that [the
    defendant] ‘shall take all prescribed medication’ is overbroad insofar as it is not
    clearly limited to medications that are reasonably related to sex offender
    treatment.”).
    AFFIRMED.
    4
    FILED
    United States v. Blatchford, No. 11-10431                                        OCT 23 2012
    MOLLY C. DWYER, CLERK
    RAYMOND C. FISHER, Circuit Judge, concurring:                              U .S. C O U R T OF APPE ALS
    I concur in the result and in the majority’s analysis but write separately to
    surface two concerns. One is that I hope our decision will not be understood by
    district courts as a signal that they should continue to use open-ended, unqualified
    language when imposing supervised release conditions requiring defendants to take
    prescribed medication. Under our case law, such conditions should either be
    supported by the findings required under United States v. Williams, 
    356 F.3d 1045
    (9th Cir. 2004), or be limited explicitly to medications that do not implicate
    significant liberty interests. Probation officers and government attorneys should
    bear this in mind when they propose conditions to district courts. And district
    courts should revise the standard language they use when imposing such
    conditions. The language used here – “which may include taking prescribed
    medication” – is facially overbroad, and could be revised to read, for example,
    “which may include taking prescribed medication, so long as the medication does
    not implicate substantial liberty interests.” Of course, the more specificity the
    court can provide, the better.
    Second, as the majority says, Blatchford must have the ability to challenge
    any specific medications prescribed during his period of supervised release. If
    1
    Blatchford participates in a mental health program that includes a prescribed
    medication that Blatchford in good faith believes implicates his liberty interests,
    Blatchford should be able to refuse to take the medication – without risking a
    supervised release violation, being taken into custody or suffering other adverse
    consequences – until the issue is resolved by the district court.
    An exchange during oral argument illustrates this concern. At argument, the
    court asked what would happen if Blatchford were prescribed disulfiram, a drug to
    treat alcoholism sold under the brand name Antabuse. According to the National
    Institutes of Health’s website, using alcohol while on disulfiram may cause
    “flushing of the face, headache, nausea, vomiting, chest pain, weakness, blurred
    vision, mental confusion, sweating, choking, breathing difficulty, and anxiety.”
    Disulfiram: MedlinePlus Drug Information, U.S. National Library of Medicine,
    National Institutes of Health,
    http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682602.html (last visited
    Oct. 17, 2012). Side effects may include headaches, drowsiness, tiredness and
    impotence. See 
    id.
     These effects may not be as profound as those associated with
    antipsychotic drugs, but, in light of the unsettled nature of our case law, I assume
    Blatchford could have a good faith belief that being compelled to take Antabuse
    would implicate his significant liberty interests. Blatchford thus should be
    2
    permitted to refuse the medication, without suffering adverse legal consequences,
    until the district court either rules that the medication does not implicate his liberty
    interests or makes the findings required by Williams.
    3